Medical treatment of cirrhotic ascites is essentially supportive, dictated by the patient's discomfort, impaired cardiovascular or respiratory function and potential for infection. Treatment of'simple' ascites (moderate fluid accumulation, serum albumin > 3.5 g/dl, serum creatinine < 1.5 mg/di, no electrolyte disturbance) is implemented sequentially. Only 10% of patients respond to dietary sodium restriction and bed rest; most require pharmacotherapy consisting of spironolactone, which increases the proportion of responding patients to 65% and loop diuretics, which may produce clinical improvement in an additional 20% (85% in all); in the remaining 15% of refractory patients, use of novel adjunctive therapies may be attempted. Patients with tense ascites, impaired renal function and electrolyte disturbances merit special consideration before diuretics are introduced. Spironolactone has long been a standard for the treatment of cirrhotic ascites because it directly antagonizes aldosterone. The loop diuretic most frequently added to spironolactone has been furosemide. However, there is preliminary evidence that torasemide may be more effective in some patients. Other investigational agents that may play a role in treatment of patients resistant to conventional drugs include ornipressin (a vasopressin analogue) and atrial natriuretic factor.
A brief overview of the pathophysiology of ascites formation in hepatic cirrhosis (1) can facilitate understanding both of the available therapeutic options and of the rationale for development of new therapeutic approaches. Traditionally, the initiating event of renal sodium and water retention in cirrhosis was considered to be ascites formation (underfilling hypothesis) or primary renal dysfunction due to a hepatorenal reflex (overflow hypothesis) (2) . The alterations of systemic, splanchnic and renal haemodynamics, as well as increases in circulating levels of substances that cause sodium retention (3) (4) (5) (6) , are compatible with a decrease in effective blood volume as suggested by the underfilling hypothesis. These alterations, however, precede ascites formation. The recently introduced vasodilation hypothesis (7) reconciles many aspects of the underfilling theory and the overflow theory; it proposes that peripheral arterial vasodilation is the initiating event leading to decreased effective blood volume and renal sodium retention ( Table 1 ) and suggests that haemodynamic, hormonal and renal changes are augmented as liver disease becomes more severe. Peripheral arterial vasodilation leads to a decrease in effective arterial blood volume and, in compensation, increases in circulating levels of renin, aldosterone, noradrenaline and vasopressin, which result in renal vasoconstriction with sodium and water retention. With increasing severity of cirrhosis, the activation of these stimulants of sodium retention cannot restore effective blood volume. This, together with a decrease in plasma oncotic pressure due to hypoalbuminaemia and an increase in hydrostatic pressure in the splanchnic vessels, results in extravasation of fluid. Once the resorptive transplantation. This article, concentrates on medical therapy for ascites which, like all procedures other than transplantation, is only supportive. Therefore, the principle of 'primum nil nocere' should always be kept in mind (11) (12) (13) .
Medical therapeutic options
capacity of the lymphatic vessels is exceeded, ascites becomes overt.
After the diagnosis of ascites is established by clinical examination and ultrasonography, the cause of the condition must be determined. The patient's medical history and results of typical laboratory assays can often reveal malignant causes (e.g. peritoneal carcinomatosis and liver metastasis) or non-malignant causes (e.g. cirrhosis of the liver). Laboratory examination of the ascitic fluid can be helpful in differentiating the cause of ascites (8) (9) (10) , particularly determinations of cholesterol, carcinoembryonic antigen and other tumour markers in addition to cell count and differentiation; bacteriologic and cytologic examinations also play an important role in differential diagnosis (Fig. 1) .
Ascites does not require treatment merely because it exists. However, most patients with ascites feel uncomfortable and their physical activity is limited. Furthermore, therapy for ascites is indicated by the impairment of cardiovascular and respiratory functions due to tense ascites and the potential development of spontaneous bacterial peritonitis. Several therapeutic options are available for the management of ascites in patients with hepatic cirrhosis: bed rest, restriction of sodium intake, diuretics, paracentesis, temporary or continuous reinfusion procedures (such as peritoneovenous shunting), portacaval or intrahepatic shunting procedures and liver Sodium balance can be achieved more easily when sodium intake is restricted. Limitation to about 50 mmol of sodium, which corresponds to approximately 3 g of dietary salt, is usually well tolerated. Lower levels of sodium intake result in less palatable diets and thus lead to poorer patient compliance; severely restricted sodium intake may also contribute to increased activation of the renin-angiotensin-aldosterone system. Bed rest alone has a diuretic effect that can augment the natriuresis induced by diuretic drugs (14) (15) (16) .
The results of randomised, controlled trials have disclosed the following about diuretictherapy:
• Sodium excretion is induced by combination therapy with spironolactone and furosemide (17) . • In the setting of cirrhosis, spironolactone alone or combined with furosemide induces greater sodium excretion than furosemide alone (18, 19) .
• Restriction of salt and water intake alone is less efficient than salt and water restriction plus the use of spironolactone or the combination of spironolactone and furosemide (20) .
Based on these findings, sequential therapy for ascites is usually recommended (Fig. 2) .
Sequential approach to ascites management
Sodium restriction and bed rest are sufficient to manage ascites in about 10% of patients. However, because an adequate response (mean reduction in body wt. ~ 400 g/day for 4 days) will not be seen in most patients, administration of spironolactone will be required. Ascites can be alleviated in approximately 65% of patients with spironolactone, the mainstay of diuretic therapy for ascites, at dosages of up to 300 mg/day orally. Addition of a loop diuretic (e.g. furosemide) at dosages of up to 120 rag/day orally increases the rate of therapeutic success to approximately 85%. In about 15% of patients, ascites remains refractory to diuretic therapy or treatment must be discontinued because of side effects, such as encephalopathy, hyponatraemia, hypokalaemia, or hyperkaemia.
Guidelines for optimum benefit
The patient with ascites should be thoroughly evaluated after treatment with a balanced sodium diet alone for at least 5 days. This clinical evaluation must include measurement of blood pressure and heart rate as well as examinations for encephalopathy and muscular and neurologic abnormalities. At the same time, serum should be analysed for concentrations of sodium, potassium, creatinine, urea, calcium, magnesium, albumin and uric acid and serum osmolality should be assessed. Recommendations also include weighing the patient dailyand analysing 24-h urine collections every other day. Urinalysis should measure concentrations of sodium, potassium and creatinine, as well as urinary osmolality, which will allow for the calculation of creatinine clearance, fractional sodium excretion and the urinary sodium/potassium ratio. In addition, laboratory examination of the urinary sediment may indicate glomerular or tubular damage. After this initial evaluation, the patient may be classified as having 'simple' or 'complex' ascites.
Managing simple ascites
Patients may be regarded as having simple ascites when there is no evidence of serum electrolyte abnormalities, hypoalbuminaemia, or encephalopathy; no major reduction in glomerular filtration rate; no outstanding sodium retention; and no more than a moderate accumulation of ascitic fluid ( Table 2 ). The condition of these patients will likely respond to the con- If simple ascites does not respond adequately to diuretic therapy, several possibilities should be considered. A lack of decrease in body weight, despite marked urinary sodium excretion, indicates a high sodium intake; this may be due to dietary noncompliance or to inadvertent iatrogenic sodium administration (e.g. antibiotics, antacids). Because amino acids increase glomerular filtration rate, a diet severely restricted in protein (e.g. to prevent encephalopathy) may impair renal function. In addition, renal function can be affected by use of cyclooxygenase inhibitors, typified by non-steroidal anti-inflammatory drugs such as indomethacin; by volume depletion resulting from lactulose-induced diarrhoea; and by overly vigorous diuresis. Furthermore, some drugs (e.g. aminoglycosides) may directly damage the renal tubule. In the absence of the preceding possibilities, a lack of response to diuretic treatment might indicate fulminant hepatitis, spontaneous bacterial peritonitis or gastrointestinal bleeding.
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Managing complex ascites
Whether complex ascites exists initially or develops during therapy, its management needs special attention. Hyponatraemia is largely caused by dilution and, therefore, should be managed with fluid restriction. Hypokalaemia demands potassium replacement or a modification of the diuretic regimen; the latter is also indicated in hyperkalaemia. Patients whose serum albumin concentration is <3.5 g/dl may benefit from the intravenous administration of salt-poor albumin (21) , although the value of this intervention has not been clearly demonstrated by clinical studies. Spontaneous bacterial peritonitis must be managed with antibiotics.
Severe hepatic encephalopathy requires treatment (e.g. by stringent dietary protein limitation, lactulose administration and, possibly, consideration of liver transplantation.
Tense ascites may be relieved initially by therapeutic paracentesis (22) ; an adequate diuretic dosage can then be established (23) . Diuretic therapy should not routinely be started in patients whose serum creatinine concentrations are > 2 mg/dl because of the risk of azotaemia and renal failure.
Minimizing side sects
Side effects of therapy for ascites may be minimized by monitoring urinary volume and electrolyte excretion and maintaining normal levels of serum electrolytes and renal function. Side effects may also be minimized by controlling body weight, blood pressure and heart rate. To avoid reducing the effective blood volume and further activating mechanisms of sodium retention in patients without peripheral oedema, diuretic dosage should be adjusted to provide a daily weight loss of no more than 750-900 g. However, patients with peripheral oedema can tolerate a daily weight .loss of _> 1.5 kg without significant side effects (23, 24) .
Investigational agents for use in refractory ascites
In the minority of patients who fail to respond to conventional therapies, which are based on bed rest, sodium restriction and administration of spironolactone (up to'a maximum of 300 mg/day) and the subsequent addition of furosemide (up to a maximum of 120 mg/day), three other agents currently under investigation may be tried. One of them, torasemide, is a loop diuretic, while the other two, atrial natriuretic peptide (ANP) and ornipressin, act as hormones.
Torasemide
A now loop diuretic, torasemide, has a bioavailability of >85% (25) . Compared with furosemide, torasemide has a longer half-life and smoother, more prolonged activity; these features may be advantageous for cirrhotic patients, who are sensitive to sudden decreases in intravascular volume.
A recent study found that in patients with ascites, torasemide induced a prolonged natriuresis and stronger diuresis than furosemide (26) . Of particular interest, patients whose ascites did not respond to administration of furosemide or to a combination of spironolactone and furosemide exhibited significantly greater natriuresis after receiving torasemide or the combination of spironolactone and torasemide, respectively (26, 27) . However, further investigation is needed to establish $7 torasemide as the preferred loop diuretic in cirrhotic patients with ascites.
Atrial natriuretic factor (ANF)
The potential therapeutic application of ANF (or its analogues) to patients with ascites has recently received attention (28, 29) despite the fact that ANF must be administered intravenously and has a short duration of action. It increases glomerular filtration rate, influences tubuloglomerular feedback and decreases the release of renin; it also inhibits the synthesis and release of aldosterone (30) . However, in animal models and patients with cirrhosis, particularly those with ascites, the renal response to ANF seems to be blunted (31, 32) . This might be due to alterations in renal ANF receptors (33) as well as to a decrease in mean arterial pressure following ANF administration in cirrhotic subjects (34) . Thus, low-dose infusions of ANF may induce greater natriuresis than high-dose infusions.
Coadministration of vasoconstrictors might prevent ANF-induced hypotension. In an animal model of portal hypertension, combination with vasopressin was shown to potentiate the natriuresis and diuresis induced by ANF (35, 36) . Clinical evaluation of such combination therapy has not yet been pursued. The development of inhibitors of the ANF-degrading prot'einase EC 3.4.24.11 or of ANF analogues that selectively bind to clearance receptors (37) may result in a longer-acting oral agent, which could prompt clinical studies. 
Ornipressin
The effects of the vasopressin analogue ornipressin were recently studied in patients with poor renal function who were treated in an intensive care unit (38) . After 2-h and 4-h infusions, peripheral vasodilation and the renal vasoconstriction reversed in part and were accompanied by a decrease in activation of the mechanisms of sodium retention and an increase in circulating levels of ANF. These effects resulted in improved renal function and sodium excretion (Fig. 3) . Ornipressin infusion thus may be helpful as a short-term intervention to improve the critical condition of such patients.
Additional alternatives
Other therapeutic approaches may prove useful, particularly in patients whose ascites is resistant to conventional diuretic therapy. The development of antagonists to block the increased synthesis of leukotrienes (39, 40) and to attenuate the effects of platelet-activating factor (41,42) might be helpful, particularly for patients with renal impairment.
